DMD treatment SMT-01, a cell replacement therapy, received FDA orphan drug and rare pediatric disease designations.

Sarepta's Elevidys approval, revenue growth projections, and competitive position make it a strong investment in DMD ...

AI-driven biotech Somite.ai scores dual FDA designations for its novel treatment, potentially fast-tracking hope for families ...

Six-year-old Cooper Wood was diagnosed with Duchenne muscular dystrophy earlier this year. When his parents applied for a one ...

A possible gene therapy approval and a series of major trials readouts set the stage for a busy year of drug development in Duchenne muscular dystrophy.

Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, ...

The FDA has granted Orphan Drug and Rare Pediatric Disease Designations to Somite’s cell replacement therapy for the ...

The U.S. Food and Drug Administration granted rare pediatric disease designation to NS-050/NCNP-03, an exon-skipping DMD ...

Green vegetables help with your oral microbiome,” says Garcia-Godoy. “This helps keep your mouth healthy—you don’t want your ...

SUZHOU, China I 9, 2024 I On 06, 2024, GenAssist Ltd (GenAssist), announced the first DMD patient dosed with its base editing drug, ...

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...